ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SXTC vs RTX // FORWARD P/E MULTIPLE

China SXT Pharmaceuticals Inc. (NASDAQ) VS. RTX Corporation (NYSE) • 15-METRIC TALLY: SXTC 0 — RTX 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SXTC VS. RTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SXTC RTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 21.90% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) — 7.20% — TIE /roic <GO>
EV/EBITDA & P/E Valuation — 26.5x — TIE /valuation <GO>
Free Cash Flow Yield — 2.95% — TIE /fcf-yield <GO>
Operating Margin -60.00% 10.50% -70.50 RTX /operating-margins <GO>
Net Profit Margin -60.00% 7.60% -67.60 RTX /net-margins <GO>
Revenue Growth (YoY) — 9.70% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 1.33% -1.33 RTX /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 2.73 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 9/9 -8.00 RTX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 27.7 60.0 -32.26 RTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.92 — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — 37.2x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $367.7K $269.08B -$269.08B RTX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SXTC REV RTX REV SXTC GROSS % RTX GROSS % SXTC FCF RTX FCF
FY 2025 $1.1M $88.60B 21.9% — -$4.0M $7.94B
FY 2024 $1.7M $80.74B 21.1% — -$2.3M $4.53B
FY 2023 $1.9M $68.92B — — -$1.9M $4.78B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SXTC // BETA —
RTX // BETA 0.92